Objective To review evidence on starting, switching, and stopping disease-modifying
therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing …

Background Currently, 19 disease-modifying therapies (DMTs) have been approved for the
treatment of patients with relapsing forms of multiple sclerosis (RMS). Objective The …

Objective To develop recommendations for disease-modifying therapy (DMT) for multiple
sclerosis (MS). Methods A multidisciplinary panel developed DMT recommendations …

Background Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central
nervous system. The treatment of MS has always been a focus of neurological research. To …

Purpose The purpose of this review is to discuss the selection and use of disease-modifying
treatments for patients with relapsing forms of multiple sclerosis (MS). Methods PubMed was …

Multiple sclerosis (MS) is a chronic inflammatory demyelinating central nervous system
disease that typically strikes young adults, especially women. The pathobiology of MS …

There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

PURPOSE OF REVIEW Given the expansion of options for the treatment of relapsing
multiple sclerosis, this review outlines the framework for developing a treatment strategy …

Introduction Randomised studies have demonstrated efficacy of disease-modifying
therapies in relapsing remitting multiple sclerosis (RRMS). However it is unclear how the …

Reviews of therapeutic drugs usually focus on the highly selected and closely monitored
patient populations from randomized controlled trials. The objective of this study was to …